In this seminar, Hudson Alakonya will be presenting the results of his PhD project where he focused on developing a novel monoclonal antibody radiolabelled with a radioisotope as a single photon emission computed tomography (SPECT) imaging agent to aid in the early diagnosis and prognosis evaluation of PDAC patients. Hudson’s work has led to the development of the first successful radionuclide imaging agent for interrogating p53 protein in living tissues (in vivo).